(1 - 9 from 24
)
BMS aims for US approval of Opdivo combo in stomach cancer
www.pmlive.com
Jan 21, — ... whom no novel therapies have been made available in the last decade,” said Ian Waxman, development lead, gastrointestinal cancers, BMS. › pharma_news › bms_aims_f...
BMS announces initial results for Opdivo plus Yervoy in liver ...
www.clinicaltrialsarena.com
Jun 4, — Bristol-Myers Squibb gastrointestinal cancers development lead Ian Waxman said: “Opdivo has been an important treatment option for patients ... › news › bms-opdiv...
BMS closes in on colorectal cancer indication for Opdivo
www.pmlive.com
Apr 5, — ... than patients with metastatic colorectal cancer without these biomarkers," commented BMS' gastrointestinal oncology lead Ian Waxman. › pharma_news › bms_closes_i...
BMS gets EC nod for Opdivo combination to treat ...
www.ns-healthcare.com
Oct 22, — Bristol Myers Squibb gastrointestinal cancers development lead Ian Waxman said: “This approval marks a great achievement for many patients ... › news › opdivo-combi...
sorted by relevance / date